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ABSTRACT
Prostate cancer is the second leading cause of cancer death in men. Prostate
Specific Antigen (PSA) is the current indicator of prostate health, and needle core biopsy
of the prostate is the standard of cancer diagnosis. However, PSA is not a specific
indicator of cancer, and biopsy may miss actual tumor cells, leading to both false positive
and false negative results, respectively. Therefore, better indicators of prostate cancer
need to be identified.
Field effect is the term used to describe the existence of genetically altered,
although histologically normal, cells that surround an area of frank cancer. Better
understanding and characterization of this field should provide more sensitive means of
detecting prostate cancer independent of histological biopsy findings that may miss the
tumor. This study furthers field characterization by analyzing various types of genomic
and epigenetic alterations, including gene promoter methylation, mRNA expression
profiling, changes in telomeres, and genomic instability as reflected by random sites of
allelic imbalance. Results demonstrate that this field is predictably altered in cancer.
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Chapter 1
Introduction

Background
Prostate cancer is the most common cancer related death in men after lung cancer
in the United States. It is projected by the American Cancer Association that
approximately 186,320 new cases will be diagnosed in 2008, with approximately 28,660
deaths-about 1 death every 16 minutes. That means there is a one in six chance of a man
developing prostate cancer over his lifetime. Additionally, prostate abnormalities related
to hyperplastic disorders, such as benign prostatic hyperplasia (BPH), prostatic
inflammatory neoplasia (PIN), and adenocarcinoma, significantly impact quality of life
due to nocturia, urinary retention, and sexual dysfunction (1). While the mechanisms of
initiation and progression of these pathologies are not yet well understood, there is a
strong correlation between advancing age and increasing incidence, with 80% of new
prostate cancer diagnoses occurring in men 65 years and older (1).
In order to better understand prostate cancer, it is necessary to know about the
normal prostate. The prostate is a small, walnut sized organ, approximately 20 grams,
located retroperitoneally and encircling the neck of the bladder and the urethra. In the
embryo, the prostate has fives lobes, but these lobes are indistinguishable in the adult
prostate. The adult prostate is divided into four anatomical regions, specifically the
peripheral, central, transitional, and periurethral regions (Figure 1). Most hyperplasias
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arise from the transitional and periurethral regions, while most (70%) carcinomas arise
from the peripheral region.

Figure 1. Zonal schematic of the prostate gland. Representation of the normal prostate
and its regions/zones. TZ=transitional zone, CZ=central zone, PZ= peripheral zone.
(http://www.ajronline.org/cgi/content-nw/full/188/5/1373)

The most common pathology of the prostate is benign nodular enlargement,
frequently referred to as benign prostatic hyperplasia (BPH). Nodules are commonly
located in the periurethral tissue, are visually distinct, and their growth has been linked to
androgen stimulation. These benign growths begin in the epithelial tissue and move into
the stromal compartment, resulting in prostates weighing anywhere from 60-200 grams or
more. The second most common pathology of the prostate is adenocarcinoma, and is
epithelial in origin. However, 90% of these tumors do not cause clinical symptoms, but
rather are discovered incidentally (2). The incidence of clinically significant prostate
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cancer is very low in men of Asian ancestry, while it is most frequently found in African
Americans, although Asians do have the same rate of latent disease as Caucasians (3).
Prostatitis is the third most common pathology, and falls into three categories, acute
bacterial, chronic bacterial, and chronic abacterial prostatitis. Prostatitis and BPH are
significant in the prostate cancer story because BPH is often found in association with
prostate cancer, both can cause symptoms similar to cancer, and both can cause prostate
specific antigen (PSA) levels to rise.
PSA is the current early indicator of prostate cancer detection. It is a serine
protease meant to cleave and liquefy seminal fluid coagulum formed in the ejaculate. In
the instance of BPH, prostatitis, and carcinoma, PSA levels in the blood become elevated.
However, this is the downfall of the PSA assay as well, as PSA cannot distinguish
between BPH and carcinoma, nor can it provide information regarding the severity of
disease. To further complicate the picture, some men simply produce higher levels of
PSA normally (4). 25-30% of BPH cases and 80% of carcinoma cases have a PSA above
4 ng/ml, a level often considered to be the limit of normal PSA range (5). Of more
concern, 20-40% of organ confined cases of prostate cancer have PSA levels in the
normal range of 4 ng/ml or less (4, 5). The other routine test to detect prostate
abnormalities is the digital rectal exam (DRE), where the prostate is palpated by a
physician. However this test also has drawbacks, as it depends on the clinical experience
of the practitioner to differentiate abnormalities and it can only detect a fairly large
abnormality. Because PSA and DRE tests are not definitively diagnostic, histology is
used to diagnose cancer of the prostate. This is done by taking 6-12 needle core biopsies
of the prostate, usually guided by ultrasound. It is possible that any tumor cells present
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may be missed in the standard six or twelve core biopsy, or multiple biopsies may be
done over time because of the elevated PSA, often to the detriment of the patient (6).
Most frightening to cancer patients following treatment with prostatectomy, PSA levels
may actually rise temporarily, causing great distress (7). Yet, to date, no better biomarker
has been found, either for detecting prostate cancer or for its prognosis (4). Taken
together, these problems cause significant distress to patients and their families (8, 9).
The prostate is a gland, and as such is comprised of glandular tissue, epithelial
cells supported by basement membrane and surrounded by stroma. The general
appearance is regular and orderly with small nuclei. Cancerous tissue frequently lacks
basal cells and a basement membrane. The nuclei are large and vacuolated and cells
contain large nucleoli. The general appearance is disorganized and irregular. The amount
of dedifferentiation evident in a biopsy is prognostic, and in order to describe the
abnormal histology, the Gleason Scale was developed. The scale runs from 1 to 5, where
1 is the most differentiated tumor and 5 is very dedifferentiated (Figure 2). The Gleason
Score is a sum of the Gleason rating of the most prevalent (>50%) abnormal histology
present, and the second score represents less than 50% but more than 5% of the observed
cancer. Another possible histological finding is prostatic intraepithelial neoplasia (PIN).
This is a transitional state between normal and cancerous histology, and is considered to
be preneoplastic. PIN is characterized by multiple foci of glands with intra-acinar
proliferation of cells with nuclear anaplasia. However there is no invasion and the basal
layer and basement membrane are intact.
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Figure 2. Gleason grading system diagram. The cartoon on the left is the pathological
guide to grades 1-5. On the right are H&E stained slides that show examples of grades 35. (http://www.prostatecancer.org/education/staging/img/Dowd_GleasonScoreFig1.jpg)

If cancer is detected in a needle core, several treatment options are available to the
patient, including radiotherapy and hormonal therapies. The definitive treatment for
prostate carcinoma is surgical, a radical prostatectomy. All of these therapies include
significant risk to the patient, the more significant risks ranging from loss of sexual
function to incontinence to death. Prostatectomy can provide additional prognostic
information, including perineural invasion, lymph node involvement, seminal vesicle
involvement, and how much of the prostate is involved. Based on these additional
5

findings, patients can be staged by the TNM staging system (Figure 3). This system takes
into account how much of the gland is involved, if lymph nodes are involved, and if there
is disseminated disease. Complications of untreated disease can seriously affect quality of
life and include metastasis and increased risk of morbidity. Advanced disease frequently
spreads to the axial skeleton, specifically the spine, and can cause both osteolytic and
osteoblastic bone lesions, although it should be noted that osteoblastic metastases are
unique to prostate cancer and occur more frequently.

Figure 3. Staging of prostate cancers. Representative rubric of prostate tumor staging
based on size (T), nodal involvement (N), and localization (M).
(http://edoc.hu-berlin.de/dissertationen/kaiser-simone-2004-06-10/HTML/chapter1.html)
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Another unique aspect of prostate cancer is its usually slowly progressing nature.
Autopsy studies of elderly men frequently reveal the presence of undiagnosed prostate
cancer that never manifested itself clinically (1). Often a man with a diagnosis of prostate
cancer will die from another cause. While the American Cancer Society states 1 in 6 men
will be diagnosed with this cancer, they also note that only 1 in 35 men will die from this
disease. Because of this, men may choose not to treat this cancer, and rather engage in
‘watchful waiting.’ This is a valid treatment modality for many men, yet it is not
appropriate for all men. PSA levels do not determine which men may benefit from
watchful waiting. Finding a prognostic marker would be beneficial in this respect,
significantly reducing the risk of mortality due to cancer and/or surgery and the risks
associated with prostatectomy, including impotence, incontinence, and death.
Carcinogenesis is currently accepted to be a multi-step process. Genetic and
epigenetic changes occur affecting the cell’s regulatory mechanisms, leading to the loss
of normal regulation and increased proliferation when these changes convey properties
that enhance cell survival (10, 11). Importantly, it has been observed that (i) these
changes are stable at the DNA level, allowing for genetic-based detection, and (ii) the
microenvironment is critical to cancer development and behavior (12). As these
mechanisms are clarified, new targets for detection, treatment, and prevention will lend
themselves to development.
Genomic instability is one hallmark of cancer progression. One type of genomic
instability, described as chromosomal instability, was first characterized by Lengauer and
colleagues (13). A tumor cell population with chromosomal instability indicates high

7

clonal heterogeneity (14). DeWever and Mareel (15) have proposed a model of intimate
interaction between tumor and stroma to explain the observed DNA changes, which also
explains a phenomena referred to as the observed field effect well. The term “field effect
refers” to the observation of genomic changes not only within tumor cells, but the
surrounding tissues as well, despite the fact that these tissues appear histologically
normal. Changes may occur along one of two pathways. In the efferent pathway, the
tumor cell exerts an effect on the surrounding stroma, causing it to secrete products such
as PDGF and TGFβ. The stroma is now termed reactive stroma as it is altered or
transdifferentiated. The afferent pathway is one by which this reactive stroma then affects
the tumor cells, releasing proinvasive signals that enhance motility and invasion
properties of cells and also reduces apoptosis. Reactive stroma also plays a role in cancer
pain and directing cancer cells to perineural invasion and dissemination (12).
This scenario requires highly specific interactions under specific conditions,
namely the environment must be receptive to some initial stimulus at the right time and
location. Experiments have demonstrated that tumors will grow when cancer cells are
seeded into reactive stroma, but not when seeded into normal stroma (12). This suggests
that the microenvironment must be created first, potentially allowing for early detection,
provided we know what genetic or epigenetic profile to look for. These alterations are not
terminal events in cancer progression, but rather are ubiquitous within a field of
genomically unstable cells during cancer progression. Because these events may be found
outside the focus of tumor cells or even before tumor cells are present, they are more
likely to be found in the tissue of a needle core biopsy. mRNA transcript levels, gene
promoter methylation, telomere alteration, and microsatellite instability are among the
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possible alterations likely to be present early in the development of prostate cancer, and
therefore may have significance in early diagnosis (16-21).
One such example of epigenetic profile alteration is GSTP1 methylation,
observed in PIA, PIN and prostate cancer, but not BPH, suggesting that some event
initiates instability, providing the driving force for prostate cancer progression (18-20,
22). Another example of genomic instability can be seen in telomeres, a naturally
inherent barrier to the development of cancer. Telomeres are specialized protein-nucleic
acid structures that protect and stabilize the ends of eukaryotic chromosomes (23, 24).
When telomere lengths are reduced beyond a critical set point, they become prone to
chromosomal fusion and breakage, normally causing activation of the p53 pathway in
healthy somatic cells, which will then progress through senescence and apoptosis (2530). These mechanisms are frequently inactivated in cancer cells, for example through
p53 and Rb mutations or hypermethylation silencing of GSTP1 or P504S (31-33).
Accordingly, telomere shortening in cancer cells is a cause of unchecked genomic
instability, including dicentric chromosome formation, chromosome translocation,
aneuploidy and loss of heterozigosity and, thus, a source of phenotypic variability (30,
34-36). In retrospective studies, our laboratory has shown that telomere content (TC), a
surrogate for telomere length, predicts clinical outcome in prostate cancer (Figure 4) (37).
Similarly, TC in tumor adjacent histologically normal (TAHN) tissue, taken 1 cm distant
from the tumor margin, also correlated well with clinical outcome in prostate cancer (38).
While the current method of measuring TC is very effective, it does not lend itself well to
direct application in the clinical setting for various reasons (39). Therefore, despite TC
providing a sensitive predictor of disease-free survival in men with prostate cancer, an
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alternative marker and/or method for use with samples containing small numbers of cells,
such as needle core biopsies, using common techniques and equipment, such as PCR, is
desirable.

Figure 4. Covariate-adjusted recurrence free survival by telomere DNA content in
prostate tumors. The cohort was divided into two groups, based on the specified values
of telomere DNA content (TC). The first group contained samples with TC >0.75
(N=49). The second group contained samples with TC <0.75 (N=28). The prostate
cancer-free survival interval, in months, is shown on the x-axis and the recurrence-free
fraction is shown on the y-axis. Censored events are indicated with ticks. (38)

Given that many types of genetic and epigenetic changes have been documented,
it seems logical that these changes should be reflected in the messenger RNA (mRNA)
produced by a cell, and that these changes should be quantifiable. And indeed, this can be
done using microarray technology, through the labeling of cDNA generated from mRNA
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and competitive hybridization to specific probes (40). This technique is becoming
common place in laboratories and is establishing unique cancer profiles. The hope in
using this technique is to identify a unique ‘signature’ for a given tumor type for use as a
diagnostic tool (41-44). Additionally, this method can also be used to identify genes of
interest, genes worth further evaluation for methylation or recombination, due to the
specificity of the probes, and the presence of several probes for each gene, revealing
splice variants. While microarray analysis requires a minimum amount of mRNA, the
rapid turn around time and wealth of data generated make this a valuable tool for rapid
assessment of the transcriptome and focusing of studies.
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Chapter 2
Rationale and Hypothesis

Rationale
Using the method for measuring telomere DNA content (TC) developed in our
laboratory (39), we previously reported an association between TC and overall survival
and biochemical recurrence (rising PSA) in a small, case-control study of 18 men with
prostate cancer (37). These findings have been confirmed by measuring TC in archival
prostate tissue obtained from a cohort of 77 men treated with prostatectomy between
1982 and 1995 (38). Most tumors were Gleason Grade of 6-7 and had not spread to the
pelvic nodes. The median age at diagnosis was 67 years. The cohort was divided into
three groups of approximately equal size based on TC and a Cox proportional hazards
model of time until recurrence or death from prostate cancer was developed (Table 1).
The variables included tumor TC, age at diagnosis, pelvic node involvement and Gleason
sum score. There was no increased risk of recurrence associated with TC values of 0.75 –
1.49. However, TC values <0.75 conferred a relative hazard of 5.02 (p=0.0132). By
comparison, the relative hazard conferred by pelvic node involvement was 6.50
(p=0.0002) and Gleason sum scores of 7, and 8 or more, were 4.54 and 5.96, respectively
(p=0.0292 and p=0.0210, respectively). Recurrence-free survival for men with TC of
>0.75, and <75, is shown in Figure 4. TC values of <0.75 predicted prostate cancer
recurrence with a specificity of 0.90 (95% CI of 0.78-0.97). Wilcoxon/Kruskal Wallis
Rank Sums Analysis indicated a statistically significant lower median TC in men whose
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Table 1: Recurrence-free survival by telomere DNA content (TC) in a cohort of 77
cancer patients, adjusted for age, Gleason score, and pelvic node involvement. 1Relative
hazard (RH) and 95% confidence intervals (CI) from Cox proportional hazards model of
time until recurrence or death from prostate cancer. 2Telomere DNA content (TC).
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cancer recurred within 6 years (p=0.012) than in men who remained free of disease
during the same time (Figure 5, left panel).

Figure 5: Association between telomere DNA content, allelic imbalance and 72month recurrence-free survival in prostate tumors. Left panel: Non parametric
Wilcoxon/Kruskal-Wallis Rank Sum analysis of the relationship between telomere DNA
content (TC) and allelic imbalance (AI) in 64 prostate tumors. TC was measured as
described in the Chapter 5. AI was based on the ratios of paired alleles’ signal intensities.
The mean ratio in 318 heterozygous loci in buccal cells from 28 healthy individuals was
1.14 (SD 0.18). Thus, 99% of loci from normal cells would be expected to have allelic
ratios less than 1.59 (i.e., mean +2.5 SD). Therefore, a site of allelic imbalance was
defined when the ratio of the paired alleles’ signal intensities was 1.6, or greater. The line
across each diamond represents the group mean. The height of each diamond represents
the 95% confidence interval for each group, and the diamond width represents the group
sample size. Right panel: Data was obtained from 53 men without prostate cancer
recurrence within 72 months after prostatectomy and men with documented distant
metastasis, biochemical recurrence (rising PSA) or death as a consequence of prostate
cancer within 72 months after prostatectomy. Data was grouped by recurrence status and
high or low allelic imbalance. High AI was defined three or more sites, low as 0-2 sites.

Based on these results, we reasoned that other direct quantitative measurement of
genomic instability would have similar prognostic value. To evaluate this possibility, we
14

investigated the relationships between AI and TC in prostate cancer tissues and the
relationship between AI in prostate cancer tissues and 6-year disease-free survival
(Figure 5). Allelic imbalance was evaluated using a PCR based assay similar to that
described previously (17, 45, 46). The AmpFlSTR® kit (Applied Biosystems, Foster
City, CA) contains reagents that amplify 16 different short tandem repeat (i.e.
microsatellite) loci within a single multiplex reaction. TC was determined using the slot
blot titration assay developed in our laboratory (39, 47). Samples were divided into two
groups, high and low, based on the extent of AI. “High” was defined as three or more
sites of AI, as determined by dividing the smaller into the larger peak height with 1.61
and above considered imbalanced, and “low” as fewer than three sites of AI. Analyzing
the data by Wilcoxon/Kruskal-Wallis Rank Sum Tests, there was an inverse correlation
between TC and AI (p=0.01, N=64), When the sample was divided based on recurrence
of prostate cancer within 6 years of prostatectomy, there was a near significant
relationship between the group of men whose cancer recurred and the group with three or
more sites of AI (p=0.08, N=53).

Hypothesis
We have previously shown that the extent of genomic instability, measured by
either AI or TC is similar in tumor and TAHN tissue (17, 38, 48). We propose that the
distribution of these molecular alterations reflects a “field” of genetically altered cells,
within which resides a subpopulation in which tumor progression has also resulted in
histological changes. We further propose that it is these genetic alterations, not the
histological characteristics of the cells that have the greater diagnostic and prognostic
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significance. It is with this in mind that we hypothesize that we will observe similar
distributions of markers of hypermethylation patterning, and gene expression profiles in
prostate tumors and TAHN tissues, which will differ from those patterns observed in
truly normal prostate tissues from men without cancer. We further hypothesize that like
TC and AI, some of these markers will differ between prostate tumors or TAHN tissues
from men whose prostate cancer did and did not recur. This approach has the potential to
define genes whose expression is essential for prostate cancer progression and markers
that can be used for both diagnosis and prognosis that are independent of frank
histological change. By doing so, more timely care and a reduction in the risk of
undesirable side effects to the patient should occur through better identification of
patients in need of treatment.

Specific Aims
To test the hypothesis of this study, several modalities will be employed. These
include gene expression analysis using spotted microarrays and genomic and epigenomic
changes measured by TC, AI and methylation status analysis. We and others have
previously shown that the extent of genomic instability, measured by either AI or TC, is
similar in tumor and TAHN tissue, and may be an independent marker of prognosis (38,
49, 50). These findings also support the field effect model. However, the field effect in
prostate cancer is still being investigated because of the likely implications involving
cancer. Avenues of investigation include gene expression analysis, which also ties into
methylation status of gene promoters, and will be a part of the focus of this study. We
will test this hypothesis by completing the following four aims.
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• Specific Aim #1: Compare methylation states of genes known to be associated with
prostate cancer, such as GSTP1, APC, RARB2, and RassF1A, between tumor cells,
patient matched TAHN tissue and normal prostate tissue from men without cancer.

• Specific Aim #2: Assess characteristic changes in gene expression with microarrays
relevant to prognosis in prostate cancer, and determine if this profile extends to
surrounding histologically normal cells.

• Specific Aim #3: Use the telomere content assay to detect and predict potential disease
relapse in retrospective studies of prostate cancer cases with patient matched negative
biopsy, positive biopsy, TAHN and tumor tissue samples.

• Specific Aim #4: Use the allelic imbalance assay to detect and predict potential
disease relapse in retrospective studies of prostate cancer cases with patient matched
negative biopsy, positive biopsy, TAHN and tumor tissue samples.
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Chapter 3
Methylation in Prostate Cancer

Specific Aim: Evaluate and compare methylation status of genes known to be associated
with prostate cancer (GSTP1, Rarβ2, APC, and RassF1A) in cancerous and histologically
normal prostate tissues to determine if epigenetic changes that may aid in the early
detection of cancer exist in TAHN tissues.

Introduction: It is commonly accepted that changes in gene expression, such as a
down-regulation and/or mutation of p53 or increased expression of growth factor genes
are ubiquitous in cancers (32). Increases or decreases of expression are often attributable
to changes in the methylation state of CpG islands, GC-rich sequences found in the
promoters of genes. CpG islands are normally unmethylated, with the exceptions of the
inactive X chromosome, imprinted genes, tissue specific genes, and those that are
developmentally regulated by methylation (51). It has been observed that tumors of
specific tissues possess additional unique methylation patterns in specific genes (4, 52,
53) and may be predictive of outcome (17-19, 33, 54-61).Some of these changes have
been observed regarding prostate cancer. Examples of genes frequently showing
promoter methylation include GSTP1, APC, RassF1A, RAR2, P504S, and CRBP1 (18,
19, 31, 56, 58, 62-64) However, most of these studies have focused on methylation of
tumor cell promoters, and have not focused on field investigation. Based on previous
studies demonstrating field effect within the laboratory, we predicted that promoter
methylation would also demonstrate field effect and should, therefore, be characterized.
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Hypermethylation is a useful assay for measuring genomic stability for several
reasons. First, methylation status is a positive assay that provides a result with a “yes or
no” answer relative to a known constant (52, 65). Second, the methylation pattern of a
particular tumor provides information on which specific genes are being turned on or off,
which can predict particular phenotypes. An example of this is GSTP1, whose expression
is associated with drug resistance and increased mortality (66). After a thorough review
of the available literature, we proposed to compare the hypermethylation status of
GSTP1, Rarβ2, APC, and RassF1A, between tumor tissue and TAHN tissue, as these had
previously been associated with prostate cancer (52, 53, 67). Based on previous studies
with AI and TC, we predicted that the TAHN tissue will demonstrate a similar pattern as
that found in the tumor. A future possibility is the detection of prostate cancer using
methylation status of specific genes to detect cancer in other sample types, specifically
TAHN tissues of core biopsies (68, 69). Using hypermethylation assays in this way could
allow for earlier, more sensitive detection of prostate cancer and reduce the number of
repeated biopsies, thus reducing risk to the patient.
Methylation-specific PCR (MSP) is a simple, efficient method of detecting
methylation of specific genes. By using gene-specific primers, the methylation state of
CpG islands can be detected from small amounts of sample DNA, including those
derived from fresh frozen samples or micro-dissected samples (65). Because increased
frequency of CpG sites indicates a possible area of methylation, detection is achieved by
using two primers, one specific to the methylated allele (M), the other specific to the
unmethylated allele (U), exploiting the sequence differences between alleles following
bisulfite treatment. Primers are designed to generate products between 80-200bp in size.
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This technique has been shown to be incredibly sensitive without loss of specificity under
optimal conditions (66, 68, 70). Sample DNA is treated with sodium bisulfite, causing the
conversion of unmethylated cytosine to uracil, without affecting methylated cytosines.
Removal of bisulfite completes the preparation of the template DNA for PCR.

Materials and Methods

Prostate sample collection, preparation, and demographics: Thirteen matched
prostate tumors and TAHN tissues excised at 1cm from the visible tumor margin,
resulting in a total of 26 samples, were obtained from the University of New Mexico
Hospital Pathology Laboratory in agreement with all University, State and Federal laws.
Tissue samples were snap frozen in liquid nitrogen immediately after collection and
stored at -70˚C. A portion of the frozen tissues (approximately 50-70 mg) was
homogenized and DNA was isolated and resuspended in TE buffer (DNeasy Kit, Qiagen,
Valencia, CA). The median age of the cohort was 58.5 years with a range was 50-71
years; all samples had Gleason scores of 3+3 or 3+4, and a Stage of T2 with the
exception of two T3 cases; all samples were node negative (Table 2).
Eight prostate samples from cancer-free controls (sudden death cases) were
obtained from the National Cancer Institute Cooperative Human Tissue Network (CHTN;
Nashville, TN), stored at -70˚C, and subjected to DNA extraction. The median age of this
set was 44.5 years, with a range of 0-79 years (Table 2). An additional fully methylated
DNA positive control, CpGenome Universal Methylated DNA, was obtained from
Millipore (Temecula, CA)
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Cell Lines: Cell lines (LnCaP, DU146, C4-2b, and PC-3) were used to verify the
performance of the assay (i.e. if the primers and sodium bisulfite treatment were
functioning properly). These lines represent a range of prostate cancer and gene promoter
methylation.

Treatment of DNA with Sodium Bisulfite: Following DNA extraction, DNA
was treated with the commercially available sodium bisulfite-based kit CpGenome fast
DNA modification kit (Millipore, Temecula, CA) to cause deamination of unmethylated
cytosines in the CpG repeats.

Detection of Gene Methylation: Primers used here were previously published
(18, 55, 58) (Table 3). Semi-quantitative methylation specific PCR (QMSP) utilized
methylated DNA specific TaqMan probes to detect methylated samples was used to
detect methylation of samples. In this technique, 1 uL of the sodium bisulfite treated
DNA was combined with 10 uL of 2x TaqMan Universal PCR Kit (Applied Biosystems,
Foster City, CA), 600 nmol of each primer, 200 nmol probe, and the remaining volume
water for a total of 20 uL. The reactions were run on an ABI PRISM 7000 real time PCR
machine with the following protocol: Initial denaturation at 95°C for 10 minutes followed
by 50 cycles of 95°C for 15 seconds then 60°C for one minute (18, 19, 56). All samples
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Table 2. Study cohort of methylation study.
Sample
S04 175
S04 4063
S04 4778
S04 8506
SUH-05-1070
SUH-05-1083
S05 1319
S05 1329
S05 2452
S05 3237
S05 3494
S05 3855
S05 8524
P7550
P7551
38166
39196
39306
38975
Z4061227E
Z4070022A

Age
64
57
71
64
60
55
57
50
53
53
60
65
52
Infant
Infant
79
43
55
46
43
26

Grade
3+3
3+3
3+4
3+3
3+4
3+3
3+4
3+3
3+3
3+4
2+3
3+4
3+4
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal

Stage
T2 N0/II
T2/II
T3 N0/III
T2a N0/II
T2a N0/II
T2c/II
T2c N0/II
T2c N0/II
T2c N0/II
T2c/II
T2a/II
T2c/II
T2c N0/II
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Table 3. Primers and probes used for Q-MSP. The left column indicates the
primer/probe designation, the right column indicates the sequence of the oligonucleotide
and fluorescent labels (for probes).

Designation
Rar-2
Forward
Rar-2
Reverse
Rar-2
Probe
-actin
Forward
-actin
Reverse
-actin
Probe
GSTP-1
Forward
GSTP-1
Reverse
GSTP-1
Probe
RassF1A
Forward
RassF1A
Reverse
RassF1A
Probe
APC
Forward
APC
Reverse
APC Probe

Oligonucleotide Sequence
5’-CGA GAA CGC GAG CGA TTC-3’
5’-CAA ACT TAC TCG ACC AAT CCA ACC-3’
5’-6-FAM-TCG GAA CGT ATT CGG AAG GTT TTT TGT AAG TAT
TT-6-TAMSp-3’
5’-TGG TGA TGG AGG AGG TTT AGT AAG-3’
5’-ACC CAA TAA AAC CTA CTC CTC CCT TAA-3’
5’-6-FAM-ACC ACC ACC CAA CAC ACA ATA ACA AAC ACA-6TAMSp-3’
5’-AGT TGC CGC GCG ATT-3’
5’-GCC CCA ATA CTA AAT CAC GAC G-3’
5’-6-FAM-CGG TCG ACG TTC GGG GTG TAG CG-6-TAMSp-3’
5’-GCG TTG AAG TCG GGG TTC-3’
5’-CCC GTA CTT CGC TAA CTT TAA ACG-3’
5’-6-FAM-ACA AAC GCG AAC CGA ACG AAA CCA-6-TAMSp-3’
5’-GAA CCA AAA CGC TCC CCA T-3’
5’-TTA TAT GTC GGT TAC GTG CGT TTA TAT-3’
5’-6-FAM-CCC GTC GAA AAC CCG CCG ATT A-6-TAMSp-3’
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were run in quadruplicate, and a promoter specific to unmethylated β-actin was used as
the internal control. To determine levels of methylation, the delta Ct of a sample was
divided by the delta Ct of β-actin and then multiplied by 100 to give a representative
methylation level. Controls included a no template control and a fully methylated DNA
control (CpGenome™ Universal Methylated DNA, Millipore, Temecula, CA). In order
for the data to be considered acceptable, there needed to be at least three data points
reflecting the threshold of detection of the probe, which were then averaged and used in
the calculation of relative methylation.

Results:
In all instances, the promoters of the genes of interest, in addition to the -actin
control, were unmethylated in DNA from normal tissues (Figure 6).
In contrast, promoter methylation for some, but not all genes was detected in
Tumor and TAHN samples (Figure 7). While the GSTP1 assay successfully identified
methylation in cell lines, it did not detect methylation in patient samples, contrary to
previously published studies of GSTP1 methylation in cancer. Rar-2 was methylated in
one instance of Tumor DNA. APC was methylated in four tumor samples, but none of the
TAHN samples (Figure 8). RassF1A displayed frequent promoter methylation in tumor
samples, and was in four samples of the matched TAHN tissues (Figure 9). See Table 4
for a summary of results.
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E3

Figure 6. DNA from disease-free prostate tissues. Included are a post-mortem DNA
sample of prostate tissue from an infant ( P7551), and six post-mortem DNA samples
from adults shown to be free of prostate disease (39306, 39196, 38166, 28975, 29206,
Z4061227E3, Z4072255A4). All samples were analyzed for methylation with the
promoters for Rar-B2, APC, Rass F1A, and GSTP-1. In all cases all gene promoters were
found to be unmethylated. B-actin was the internal reference control used to normalize
assay results (not shown). ND=not detected.
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Relative percent methylation

Patient results
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3494 3855 3855
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T
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8506
1cm
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8506 T
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4778 T

RassF1A

RassF1A

3237
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RassF1A

3237 T

RassF1A

1329 T

RassF1A

1319 T

RassF1A
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1083 T
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175
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RassF1A

0

8542 T

Figure 7. Patient sample methylation status. Results to date of tumor and matched
NHN tissue. The X axis denotes the patient sample, tissue type (T=tumor, 1cm=NHN).
Shown on the Y axis is the relative percent methylation. To determine relative percent
methylation, the delta Ct of the sample is divided by the delta Ct of unmethylated β-actin
and then multiplied by 100.
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1070 T

3237 T

8506 T

8542 T

Sam ple

Figure 8. Methylation of the APC promoter. APC was only found to be methylated in
the tumor tissue of four patients in the set of thirteen patients analyzed. The X axis
denotes the patient sample, tissue type (T=tumor, 1cm=NHN). Shown on the Y axis is the
relative percent methylation. To determine relative percent methylation, the delta Ct of
the sample is divided by the delta Ct of unmethylated β-actin and then multiplied by 100.
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RassF1A

Relativ e M ethy lation
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0
175 T
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3237 T
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8506 1cm

Figure 9. Methylation of RassF1A in matched patient samples. The X axis denotes
the patient sample, tissue type (T=tumor, 1cm=NHN). Shown on the Y axis is the relative
percent methylation. To determine relative percent methylation, the delta Ct of the
sample is divided by the delta Ct of unmethylated β-actin and then multiplied by 100.
RassF1A was found to be methylated in ten patient samples; shown here are the four
matched patient samples of tumor and NHN tissue found to be methylated.
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Table 4. Summary of methylation results.
Sample set

Gene

Positive for
methylation

Tumor

RarB2

1/13

n=13

RassF1a

9/13

APC

4/13

1cm

RarB2

0/13

n=13

RassF1a

5/13

APC

0/13

Normal

RarB2

0/8

N=8

RassF1a

0/8

APC

0/8
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Discussion:
While global de-methylation is associated with the cancer genome, it is well
known that methylation silencing of individual genes is also common. GSTP1
methylation is a well established phenomenon in cancer cells. However, while several
studies have evaluated many genes, including GSTP1, RassF1A, Rar-2, and APC, these
studies have been plagued by a lack of proper controls, in that studies need to include
truly normal, disease-free tissue, not tumor adjacent tissues, for establishing a base line
level of methylation. This is particularly important in methylation studies where variable
levels of methylation have been observed not only in tumors but in other pathologies of
the prostate as well. This study endeavored to demonstrate why this is important by
showing the existence of a field of altered cells in the tissues surrounding the tumor. As
illustrated by the Rar-2 results, this field of alteration does exist around a tumor, but as
evidenced by the APC results, the extent of alterations in adjacent tissue is variable. This
is particularly important as the methylation pattern of particular genes appear to differ in
tumor and TAHN tissues. While this study is not definitive, it does agree with published
data, particularly the Mehrotra study (20), and indicates that further investigation of these
genes is warranted. Further investigation may lead to a new diagnostic tool to detect
prostate cancer with out the presence of tumor cells in a biopsy, as well as differentiate
between cancer and other pathologies such as PIN and BPH.
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Chapter 4
Microarray and Prostate Cancer Field Effect

Specific Aim: Assess characteristic changes in gene expression by spotted microarray
analysis of tumor and TAHN tissues to investigate the field effect.

Introduction: The terms “field cancerization” or “field effect” were first
introduced in tumors of the head and neck to describe the occurrence of genetic
alterations in histologically normal tissues adjacent to tumors (71-74). Such alterations
outside of the histologically visible tumor margins could result from pre-existing fields of
genetically compromised cells in which the tumor develops. Alternatively, the tumor
could influence the surrounding tissue, or it may reflect a combination of these two
scenarios. While the underlying mechanisms of field cancerization remain unclear, its
occurrence has been described in several epithelial cell derived tumors, including but not
limited to lung, esophageal, colorectal, breast, and skin cancers (71, 74, 75). In contrast,
relatively little is known about field cancerization in prostate cancer, perhaps due to its
previously reported multifocal nature (75, 76). In addition, prostate cancer is often
present in the setting of other benign prostatic conditions, most frequently benign
prostatic hyperplasia (BPH), which could influence adjacent cells and thus affect the
characterization of field cancerized tissue. Finally, due to the relatively small size of the
human prostate, the entire organ may be affected, either genetically or biochemically,
excluding the existence of matched, truly normal, i.e. entirely unaffected tissue from the
same patient.
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Field cancerization is of clinical importance (75). In prostate cancer, markers of
field cancerization may be important for confirming or detecting disease in biopsies after
abnormal prostate specific antigen (PSA) and/or digital rectal examination (DRE), the
current standard of care for detecting prostate cancer. PSA screening has led to earlier
detection and an overall decrease in prostate cancer specific mortality, emphasizing the
importance of prostate biopsies (77, 78). However, biopsy tissue represents a very small
portion of the prostate and consists primarily of tumor adjacent histologically normal
(TAHN) tissue. In spite of ultrasound guidance, it is easy to miss a small focal
malignancy. The current accuracy of prostate cancer detection/confirmation by biopsy is
approximately 25% with the rest representing false negative diagnoses (79, 80). In the
presence of an abnormal PSA and/or DRE, this represents a dilemma for the patient and
his physician. Therefore, biomarkers that are indicative of disease, yet independent of
histology, i.e. present in field cancerized TAHN tissue, could greatly increase the
accuracy of early prostate cancer detection in biopsies (75).
Our laboratory has previously investigated the nature of field cancerization in
both prostate and breast cancers using markers of genomic instability, including telomere
DNA content (TC), an established surrogate measure of telomere length, and the extent
of allelic imbalance (AI) (17, 38). These studies have shown telomere alterations and the
presence of AI in both tumor and TAHN tissues. In particular, alterations in TC seen in
prostate tumors were frequently mimicked in the matched TAHN tissues, indicating
prostatic field cancerization (38). Based on these observations, we hypothesized that the
molecular changes would not be limited to genomic instability, but may include
consistent alterations in gene expression. To test this hypothesis, we conducted a proof-
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of-principle study utilizing microarray expression analysis of cancerous and TAHN
prostatic tissues isolated at 1cm from the visible tumor margin. We report here the
identification of consistently altered gene expression in TAHN tissues indicative of field
cancerization in prostate cancer.

Materials and Methods
Prostate sample collection, preparation, and demographics. Twelve matched
prostate tumors and TAHN tissues excised at 1cm from the visible tumor margin
(approximately 150 mg each), resulting in a total of 24 samples, were obtained from the
University of New Mexico Hospital Pathology Laboratory in agreement with all
University, State and Federal laws. Tissue samples were snap frozen in liquid nitrogen
immediately after collection and stored at -70˚C. A portion of the frozen tissues
(approximately 50-70 mg) was homogenized and RNA was isolated and resuspended in
RNase-free water (Qiashredder and RNeasy Kits Qiagen, Valencia, CA). The median age
of the cohort was 57 years with a range was 51-71 years; all samples had Gleason scores
of 3+3 or 3+4, and a Stage of T2 with the exception of two T3 cases; all samples were
node negative (Table 5).
Samples were randomized into 2 groups, the microarray set (MA set, Table 1) and
the validation set (VA set, Table 5). Each group consisted of 6 patient matched tumor and
TAHN samples; the MA samples were those designated 1-6, while the VA set were the
samples designated 7-12 in Table 5. Three matched sets of tissue (approximately 50-70
mg per sample) from both the MA and VA sets were formalin fixed and paraffin
embedded for sectioning and hematoxylin & eosin (H&E) staining for independent
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Table 5. Description of prostate samples used in the microarray study. The cohort
consisted of (i) 12 tumor and matched tumor adjacent histologically normal (TAHN)
human tissues collected at the University of New Mexico Health Sciences Center and (ii)
6 normal, cancer-free prostates obtained from the Cooperative Human Tissue Network.
Sample

Patient’s Age

Gleason Score1

TNM Stage1

58
57
71
64
53
57
51
60
50
55
64
53

3+3
3+3
3+4
3+3
3+3
3+4
3+4
3+4
3+3
3+3
3+3
3+4

T3/III
T2/II
T3 N0/III
T2a N0/II
T2c N0/II
T2c N0/II
T2c/II
T2a N0/II
T2c N0/II
T2c/II
T2 N0/II
T2c/II

46
55
43
79
26
43

na2
na
na
na
na
na

na
na
na
na
na
na

Tumor/TAHN
1
2
3
4
5
6
7
8
9
10
11
12
Normal
13
14
15
16
17
18
1

Tumor Nodes Metastasis (TNM) stage was assigned using criteria published by the

American Joint Committee on Cancer (http://www.cancerstaging.org/index.html).
Gleason scores and Stages were determined from the prostatectomy samples.
2

Not applicable.
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pathological review (Figure 10). For the six cases chosen for microarray analysis, a total
of 1μg of the isolated RNA was pooled to generate the MA set, while the remaining
RNAs and RNAs from six additional cases (independent VA set) were stored separately.

Figure 10. H&E staining of representative prostate tissues. H&E staining of 3 cancerfree normal prostate tissues (A-C) and 3 representative cases of tumor and tumor adjacent
histologically normal (TAHN) tissues (D-F; cases 5, 6, and 8 in Table 1). A-C are at 40x
magnification; D-E are at 200x magnification; arrows and asterisks denote glandular
(ductal epithelial) and stromal areas, respectively; diamonds in D-TAHN and E-TAHN
denote corpora amylacea (sedimented sulfated glycosaminoglycans) often seen in normal
prostatic tissues (81).
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Six prostate samples from cancer-free controls (sudden death cases) were
obtained from the National Cancer Institute Cooperative Human Tissue Network (CHTN;
Nashville, TN), stored at -70˚C, and subjected to RNA extraction and histological review.
The latter confirmed these samples to be cancer-free and also free of BPH (Figure 10).
The median age of this set was 44.5 years, with a range of 26-79 years (Table 8).

Microarray expression analysis. RNA integrity was analyzed using the Agilent
Bioanalyzer 2100 (Agilent, Foster City, CA). RNAs from six matched tumor and TAHN
tissues were selected to be prepared for microarray analysis based on RNA quality and
quantity (the MA set). RNA from the selected samples was combined in equal parts to a
total of 1μg to generate the tumor and TAHN pools for the MA set. Control RNA for
microarray analysis was obtained from Ambion (Austin, TX). This consisted of RNA
pooled from 9 Caucasian donors without prostate cancer (sudden death cases), and a
median age of 70 years (range of 45-79 years).
RNA was reverse transcribed into complementary DNA (cDNA) using the
Retroscript™ RT Kit (Ambion, Austin, TX), followed by labeling with either Cy3
(pooled control RNA) or Cy5 (either tumor or TAHN pool) fluorescent cyanine dyes.
Labeling was achieved by synthesizing the cDNAs in the presence of amino allyl dUTP
(Sigma-Aldrich, St. Louis, MO) followed by chemically coupling of either Cy3 or Cy5
monofunctional dye (Amersham-Pharmacia Biotech, Arlington Heights, IL) to the
cDNA. This process avoids biased incorporation of the dyes during reverse transcription.
Glass-slide-spotted-expression microarrays of the Qiagen Human Genome Oligo
Set Version 3.0 (Qiagen) were used for this investigation. The arrays contained 37,123
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transcripts, including 24,650 known genes, the rest being expressed sequence tags (ESTs)
and controls. The design of these arrays is based on the Ensembl Human 13.31 Database
(http://www.ensembl.org/) and on the Human Genome Sequencing Project. Equal parts
of Cy3 and Cy5 labeled cDNAs were then combined and competitively hybridized to the
microarray slides using the GeneTAC Genomic Solutions machine and protocol
(Genomic Solutions Inc, Ann Arbor, MI). Following hybridization and washing, the
slides were scanned at 532nm and 635nm using the Axon 4000A scanner (Axon
Instruments, Union City, CA), and the signal data was processed using Axon GenePix
Pro 5 software (Axon Instruments). Fluorescence intensities of the Cy3 and Cy5 dyes
were determined for each oligonucleotide spot, followed by visual inspection prior to
importing into Acuity 3.0 (Molecular Devices, Sunnyvale, CA). This program was
utilized to normalize the data and allow for comparison between the replicates using
standard quality calls (background removal, linear regression ratio >0.6, signal to noise
ratio >3.0). Only data passing these quality filters were utilized in the present analysis.
Sample groups, i.e. tumor and TAHN pools, were run in triplicate hybridizations.

Quantitative (real time) reverse transcriptase PCR. Quantitative Real Time
PCR (qRT-PCR) was used to verify the results of the microarray expression analyses.
Samples from both the MA and the independent VA sets were individually analyzed in
quadruplicate for each selected gene/primer set. Approximately 1 μg of RNA from the
samples was converted to cDNA using the Retroscript™ RT Kit (Ambion) according to
the manufacturer’s protocol using random decamers. The cDNAs were subsequently
diluted 1:5 for use in the PCR reactions.
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Genes included in mRNA expression evaluation included early growth response
protein 1 (EGR-1), tristetraprolin (TTP), testican, fatty acid synthase (FAS), tissue
inhibitor of metalloproteinase 2 (TIMP2), and superoxide dismutase 2 (SOD2). mRNA
levels were quantitated using the Sybr Green real-time PCR assay kit (Applied
Biosystems, Foster City, CA) in a 25uL reaction, using 0.5uL of the diluted cDNA.
Primers were used at a final concentration of 400 uM for both the forward or reverse in
each reaction with the exception of EGR-1, for which the forward primer was used at a
final concentration of 1 μmol, the reverse at a final concentration of 1.5 μmol in the PCR
reaction. The primers’ sequences are listed in Table 9. PCR reactions were carried out
under the following cycling parameters: 95˚C for 10 minutes followed by 40 cycles of
95˚C for 15 seconds, and 60˚C for one minute using the Gene Amp 7000 Sequence
Detection System (Applied Biosystems). Baseline fluorescence was determined during
cycles 6-15.
The levels of EGR-1, TIMP2, and SOD2 were determined using the ΔΔCt
method, where the threshold of detection of the genes of interest were compared to a
house keeping gene, either the TATA binding protein (TBP) (for EGR-1), or
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (for TIMP2 and SOD2). This
method was chosen because the amplification efficiencies of their primers were
determined to be similar to the ones of the control transcripts. The remaining genes, i.e.
FAS, TTP, and testican, were evaluated using quantitation compared to serial dilutions of
plasmids carrying cDNAs for these transcripts. Expression level calculations were
controlled by the PCR efficiency corrected comparative quantitation method. Plasmids
containing FAS, TTP, testican, and TBP PCR fragments were constructed using the
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pGem T-Easy vector (Promega Corporation, Madison, WI), and the PCR product
incorporation was verified by sequencing. The data was reported as relative expression of
genes of interest in tumor and TAHN RNA compared to expression levels in the pooled
control prostate RNA.

Statistics. qRT-PCR results obtained from the microarray and validation sets
were analyzed using JMP IN version 3.2.1 from Statistical Analysis Software (SAS;
Cary, NC). Differences in the means between tumor or TAHN and cancer-free samples
were analyzed using unpaired two sample t-test; differences between matched tumor and
TAHN samples were analyzed using paired two sample t-test; differences with p<0.05
were considered statistically significant.

Results:
Microarray expression analysis. We report RNA expression levels as ratios of
Cy3/Cy5 signals for individual transcripts, where the Cy3 and Cy5 fluorescent cyanine
dyes were used to label cDNA from experimental (tumor or TAHN) and pooled cancerfree control tissues, respectively. While a ratio of 1.0 would thus indicate no change in
expression compared to cancer-free controls, there is the possibility of dye bias due to
differential incorporation of Cy3 and Cy5 during cDNA synthesis, or due to differential
hybridization of Cy3- and Cy5-labeled cDNAs to target probes. To estimate the extent of
potential dye bias, we labeled paired aliquots of control cDNA from cancer-free prostatic
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Table 6. Primers used for qRT-PCR validation of microarray experiments.
Gene

Forward Primer (5’-3’)

Reverse Primer (5’-3’)

Product
(basepairs)

Gene of Interest
EGR-1
FAS
Testican
TTP
TIMP2
SOD2

GAGCAGCCCTACGAGCAC
AGAACTTGCAGGAGTTCTGGGACA
TGGAACCGCTTTCGAGACGATGAT
GTTACACCATGGATCTGACTGCCA
TGCAATGCAGATGTAGTGATCAGG
GC
AGCATGTTGAGCCGGGCAGTGT

AGCGGCCAGTATAGGTGATG
TCCGAAGAAGGAGGCATCAAACCT
CACACACTTTGTGAGGGCTGCATT
AGTCCCTCCATGGTCGGATGG
GGGTTGCCATAAATGTCGTTTCCAG

130
149
124
86
80

TGCTTCTGCCTGGAGCCCAGATAC

74

TTTTCTTGCTGCCAGTCTGGAC
TCCACCACCCTGTTGCTGTA

112
70

Loading Control
TBP
GAPDH

CACGAACCACGGCACTGATT
ACCACAGTCCATGCCATCAC
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tissues with Cy3 and Cy5, combined equal amounts of the preparations, and hybridized
them to a microarray set. Fluorescence analysis revealed a mean Cy3/Cy5 ratio of 1.27 ±
0.35 standard deviation (SD), a median ratio of 1.22, and a coefficient of variation of
27.3% for all transcripts (Table 10). In contrast, the means ± SD and coefficients of
variation determined for the TAHN and tumor experimental sets were 1.58 ± 0.61 and
38.6%, and 1.63 ± 0.75 and 46.1%, respectively. Statistical analysis for the distribution of
values for all detected transcripts revealed significant differences (p<0.05) for the tumor
and TAHN microarray data from the Cy3/Cy5 dye bias test (Table 7). While this result
indicated a minimal dye bias for Cy3 fluorescent cyanine cDNA incorporation and/or
target hybridization, we considered all transcripts in the experimental sets with an
expression ratio of <1.27 as equally or under-expressed compared to normal cancer-free
prostatic tissues in order to avoid false positive assignment of over-expressed genes.
Consideration of the Cy3/Cy5 dye bias is important because we focused our analyses of
the microarray expression experiments on over-expressed transcripts, since overexpression of a protein marker in TAHN tissues would be amenable to positive
identification and could thus be used in diagnostic tests.
In the microarrays, 3769 transcripts were mutually expressed in both tumor and
TAHN tissues, 1810 of which were expressed above the Cy3/Cy5 dye bias of 1.27. We
plotted the expression levels for these mutually expressed transcripts and analyzed their
correlation between tumor and TAHN tissues (graphically shown Figure 11).
Logisticregression analysis indicated a correlation coefficient R2 of only 0.09, indicating
overall poor concordance of the expression levels between tumor and TAHN tissues. The
majority of these transcripts, i.e. 94% were expressed at <2.0xSD of the mean expression
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Table 7. Dye bias control. Cy3/Cy5 fluorescent dye bias control microarray
hybridization compared to experimental set using tumor and matched tumor adjacent
histologically normal (TAHN) tissues.

Mean1 ± SD
Median

TAHN

Tumor

Cy3/Cy5 Dye Bias
Test

1.58 ± 0.61

1.63 ±
0.75

1.27 ± 0.35

1.49

1.51

1.22

Coefficient of Variation
38.6*
46.1*
(%)2
1
Mean ± standard deviation (SD) for all transcripts detected.
2

27.3

* denotes significant difference (p<0.05) from Cy3/Cy5 dye bias test.
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(see Table 10) of all transcripts expressed in tumor and TAHN tissues (i.e. <3.13 and
<2.80, respectively), as shown in quadrant I of Figure 11.

Figure 11. Analysis of microarray expression. Scatter plot of 1810 transcripts (open
circles) mutually expressed at >1.27 compared to cancer-free prostatic samples in tumor
and TAHN tissues as analyzed by microarray analysis (unknown transcripts included).
Expression in tumor and TAHN tissues is shown on the log-scaled x-axis and y-axis,
respectively. The Cy3/Cy5 dye bias and the 2xSD thresholds (as defined in Table 3) are
indicated by arrows and dotted lines. The solid line shows the best fit by logistic
regression analysis accompanied by correlation coefficient R2. Quadrant I: Transcripts
expressed at <2.0xSD of the mean expression (see Table 3) of all transcripts expressed in
tumor and TAHN tissues (i.e. <3.13 and <2.80, respectively); quadrant II: Transcripts
expressed at >2.0xSD of the mean expression in TAHN and at >1.27 in tumor tissues;
quadrant III: Transcripts expressed at >2.0xSD of the mean expression in both TAHN
and tumor tissues; quadrant IV: Transcripts expressed at >2.0xSD of the mean expression
in tumor and at >1.27 in TAHN tissues.
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We used over-expression in the tumor tissues as a guide for the selection and
further analysis of transcripts in the TAHN tissues. Accordingly, we identified the
transcripts that were over-expressed in the tumor tissues at >2.0xSD of the mean, i.e. all
transcripts with a ratio >3.13. Omitting expressed sequence tags (ESTs) and unknown
open reading frames (ORFs), this identified 120 known transcripts over-expressed in
tumor tissues. Of these, 97 transcripts were also expressed in the TAHN tissues, 70 of
which were also expressed at >1.27, i.e. above the Cy3/Cy5 dye bias threshold (quadrants
III + IV, Figure 11). Eighty-three transcripts were over-expressed in the TAHN tissues at
>2.0xSD of the mean, i.e. all transcripts with a ratio >2.80 (quadrants II + III, Figure 10).
Due to space limits, we show the top 40 unique transcripts mutually over-expressed in
tumor and TAHN tissues resulting from these analyses in Table 8. The number of
mutually expressed and known transcripts at >2.0xSD for both tumor and TAHN tissues
was 10 (quadrants III, Figure 10).

qRT-PCR validation of microarrays. As shown in Figure 8, microarray analysis
indicated extensive heterogeneity of expression between tumor and TAHN tissues for the
majority of transcripts. However, our microarray expression results represent mean
values generated using pooled RNA populations. Therefore, it was important to estimate
the extent of heterogeneity in individual samples. For this, we used qRT-PCR to test and
validate the findings of the microarray expression analysis on selected transcripts in RNA
samples of tumor and TAHN tissues compared to normal cancer-free prostate tissues. To
better characterize the extent and heterogeneity of prostatic field cancerization in
individual samples, we deliberately chose transcripts from above, below and at the
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2.0xSD threshold of the mean in TAHN transcripts (i.e. ~2.8-fold over-expressed
compared to cancer-free tissues, as defined in Table 7). Early growth response protein 1
(EGR-1) represents the transcript most over-expressed (8.92-fold) in TAHN tissues and
has been previously implicated in prostate tumorigenesis (82-89). Its expression in tumor
tissue was 9.27-fold (Table 8). Testican, also known as SPOCK-1, was over-expressed at
4.29-fold and 1.73-fold in tumor and TAHN tissues, respectively. Testican has recently
been shown to be expressed in prostatic tissues (90). Fatty acid synthase (FAS) represents
an expected change in tumorigenesis of the prostate (91, 92) and was over-expressed at
5.31-fold and 1.93-fold in tumor and TAHN tissues, respectively. In contrast,
tristetraprolin (TTP) has not been previously reported to be associated with prostate
tumorigenesis and may thus represent a novel finding. It was expressed at 5.81-fold and
2.75-fold in tumor and TAHN prostatic tissues, respectively (Table 8). For control
purposes, we also included two transcripts that were equally or under-expressed in either
tumor or TAHN tissues, i.e. tissue inhibitor of metalloproteinase 2 (TIMP2) and
superoxide dismutase 2 (SOD2), expressed at 0.46-fold and 1.06-fold, and at 1.04-fold
and 0.42-fold in tumor and TAHN tissues, respectively. qRT-PCR validation was first
performed on the six individual RNA samples pooled and used in the microarray
expression analysis, the microarray (MA) set (Figure 12). In this analysis, the expression
levels were compared to 6 normal cancer-free prostate control samples. Although
variation was observed, mean expression of FAS, TTP, EGR-1 and testican in TAHN
tissues was significantly different from normal controls (p<0.05; p range = 0.01-0.03).
Similarly, mean expression for these transcripts in tumor tissues was significantly
different from normal controls (p<0.05; p range = <0.01-0.03). In contrast, and as
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Table 8. Top 40 microarray transcripts. Top 40 transcripts mutually over-expressed in tumor and
corresponding matched tumor adjacent histologically normal (TAHN) tissues compared to normal cancerfree prostatic tissue. 1 Gene identification number, Ensembl Human 13.31 Database
(http://www.ensembl.org). 2 Cy3/Cy5 ratios of tumor or TAHN (Cy3) compared to cancer-free normal
(Cy5) tissues. 3 The 4 transcripts evaluated by qRT-PCR (Figure 3) are in bold. 4 The shaded area
represents transcripts above the 2xSD of the mean in TAHN tissues.

Gene ID1
H200019156
H200003548
H200009720
H300013105
H200005926
H300013389
H300011237
H300020290
H300017466
H200000319
H200019945
H300015296
H200000676
H200006111
H200012441
H200020421
H300005679
H300014629
H300022633
H300014182
H300012307
H300015765
H300016106
H300021922
H300014306
H200014240
H300004950
H300017343
H200017342
H300005700
H300012280
H200003843
H300016780
H200006197
H300016292
H200013682
H300014868
H300004833
H200019551

Gene Description
Early growth response protein 1 (EGR-1)3
Proto-oncogene protein c-Fos
Growth/differentiation factor 15 (GDF-15), macrophage inhibitory cytokine-1 (MIC1)
ETS-domain protein ELK-4
Metallothionein-IE (MT-1E)
Copine IV
Ergic-53-like protein precursor
Molecule possessing ankyrin repeats induced by lipopolysaccharide
Early response protein NAK1, TR3 orphan receptor
Aminopeptidase N
Tristetraprolin (TTP)3
Casein kinase I (CK1)
Transcription factor Jun-D
BTG2 protein
Glandular kallikrein 1 precursor
Paired immunoglobulin-like receptor beta
Calreticulin precursor (CRP55), calregulin
Tumor protein D52
Similar to postmeiotic segregation increased 2-like 5
Neprilysin
Vascular endothelial growth factor A precursor (VEGF-A)
Colorectal mutant cancer protein (MCC protein)
Transcription factor EB
Ubiquitin-protein ligase NEDD4-like
HTPAP protein
Poliovirus Receptor related protein (CD112 antigen)
Claudin-4
Fatty acid synthase (FAS)3
Prostein protein
Keratin, cytokeratin 8 (CK 8)
Prostate specific antigen (PSA) precursor, kallikrein 3
Diamine acetyltransferase
Dolichyl-diphosphooligosaccharide-protein glycosyltransferas, 63 KD subunit
NDRG1 protein
Ubiquitin-conjugating enzyme E2-like
X box binding protein-1 (XBP-1)
KIAA0220-like protein (similar to nuclear pore complex interacting protein)
Testican (SPOCK-1)
Sialidase 1 precursor
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TAHN2

Tumor2

8.924
4.134
3.964
3.704
3.684
3.624
3.374
3.094
2.944
2.854
2.754
2.66
2.64
2.60
2.58
2.54
2.45
2.43
2.42
2.41
2.37
2.31
2.24
2.23
2.23
2.10
1.97
1.93
1.92
1.90
1.89
1.87
1.86
1.86
1.83
1.82
1.77
1.73
1.72

9.27
9.50
6.68
3.28
3.86
3.43
3.43
5.33
4.03
5.85
5.81
3.77
3.45
3.40
4.06
3.36
4.79
3.88
3.83
4.34
3.32
3.25
3.19
5.52
4.08
3.71
4.09
5.31
3.56
3.31
3.15
6.63
3.27
3.48
3.24
5.12
3.54
4.29
5.40

expected, mean expression of the control transcripts TIMP2 and SOD2, which were
equally or under-expressed in either tumor or TAHN tissues in the microarray
experiments, was similar in TAHN and tumor tissues, as well as in normal controls
(p>0.05; p range = 0.27-0.70). Although not necessarily expected due to a higher degree
of heterogeneity in cancerous tissues, expression of all of these transcripts was similar in
TAHN and tumor tissues (p>0.05; p range = 0.07-0.59), with the exception of FAS
(p=0.02). Thus, the results obtained with six individual RNA samples analyzed by qRTPCR confirm the conclusions drawn from the analysis of pooled RNA by microarray
expression analysis.
To corroborate these findings from the MA set, we also individually analyzed
RNA from six independent tumors and patient matched TAHN tissues, the validation
(VA) set. As in the MA set, mean expression of FAS, TTP, EGR-1 and testican in TAHN
tissues was significantly different from normal controls (p<0.05; p range = <0.01-0.03),
demonstrating a consistent gene expression signature in TAHN tissues. In the VA set,
mean expression of these transcripts in tumor tissues showed extensive variation when
compared to normal controls, with EGR-1 and TTP showing significant and near
significant differential expression (p<0.01 and p=0.06, respectively), and FAS and
testican showing similar expression (p=0.10 and p=0.27, respectively). As expected, the
control transcripts TIMP2 and SOD2 showed similar expression in TAHN and tumor
tissues, and in normal controls (p>0.05; p range = 0.28-1.00). Collectively, the qRT-PCR
data (Figure 12) was in excellent agreement with the data from the microarrays, thereby
indicating the occurrence of field cancerization for the selected transcripts in TAHN
when compared to tumor and cancer-free tissues.
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Figure 12. qRT-PCR validation of genes. RNA expression levels by qRT-PCR of FAS
(A), TTP (B), EGR-1 (C), testican (D), and the control transcripts TIMP2 (E), and SOD2
(F) normalized to either GAPDH or TBP. The tissue groups are indicated on the y-axis
(MA, microarray set; VA, validation set; TAHN, tumor adjacent histologically normal).
Expression is shown on the y-axis relative to cancer-free normal prostatic tissues, dots
represent the distribution, and the horizontal line indicates the median. The numbers
represent the p-values for differences between indicated groups as determined by the
unpaired (compared to cancer-free tissues) and paired (compared to matched tissues) ttest.

Discussion:
The major finding of this study is the occurrence of field cancerization in tumor adjacent
histologically normal (TAHN) human prostatic tissues, as shown by microarray and qRTPCR expression analysis of 12 mostly early stage (T2-T3) and low grade (Gleason sum 67) prostate tumors. In this study, we focused on the identification of transcripts that were
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over-expressed in both tumor and TAHN prostatic tissues, as such transcripts encode
proteins that define field cancerization. Proteins from field cancerized prostatic tissues
may have important clinical applications, especially for the alternative or adjunct
diagnosis of prostatic malignancy after inconclusive or false negative biopsy assessment.
Dhir and colleagues have reported on the identification of early prostate cancer antigen
(EPCA), a biomarker that is expressed throughout the prostate of individuals with
prostate cancer but not in those without the disease, also indicating field cancerization
(21). The authors of that study showed that EPCA staining by quantitative
immunohistochemistry resulted in minimal overlap between samples from patients with
prostate carcinoma and controls, and reported a sensitivity of 84% and a specificity of
85% in identifying individuals with prostate cancer >5 years earlier than currently used
diagnostics.
Several expression studies have reported unique molecular signatures for prostate
cancer by comparing cancerous to histologically cancer-free adjacent tissues and
attempting to link the gene profiles to clinicopathological patient information such as
stage and Gleason sum scoring (93-100). However, the use of matched tissues as
appropriate controls has been questioned due to field cancerized cells harboring genetic
and biochemical alterations (101). This is supported by our prior (17, 38) and present
results. In contrast, few expression studies have reported molecular signatures and
individual markers characteristic of prostatic TAHN tissues. Field cancerization is
however evident at the genetic as well as the epigenetic level, as we have shown by
altered telomeres in whole tissue TAHN extracts (38) and as shown by others by gene
promoter methylation of APC, RARβ2, and RASSF1A (20). Field cancerization in

50

prostatic tissues is also evidenced by RNA/protein expression analysis (40, 102). In a
similar study with a focus on signatures rather than single transcripts and without
validation by qRT-PCR, Chandran and colleagues reported on up to 254 differentially
expressed transcripts when comparing tumor associated matched tissues to cancer-free
controls utilizing an Affymetrix platform of ~63,000 probes (40). Of note, the authors
claim that the majority of these transcripts would not be identified as differentially
expressed when compared to tumors. Due to different platforms, patient populations, and
sample preparations, it is difficult to compare findings between studies. For example,
while the exact distance of TAHN tissue from the tumor is not known in most published
studies, we have carefully chosen a defined distance of 1cm. Despite differences,
similarities reported by different groups corroborate the occurrence of field cancerization.
Accordingly, Yu and colleagues have recently shown field cancerization in prostatic
tissues at the expression level using gene chip technology on a set of 152 samples (102).
Although these authors were mainly concerned with the comparison between tumor and
matched tissues, they also reported expressional differences between prostatic TAHN and
tissues from cancer-free control donors. Of interest in their study, the transcription factor
c-Fos was over-expressed 2.55-6.80 and 4.67-6.67 in TAHN and tumor tissues,
respectively. This is similar to our own findings of 4.13-fold and 9.50-fold overexpression in TAHN and tumor tissues, respectively (Table 12).
In the present study, we chose to use bulk tissue that was not microdissected in
order to include both glandular (epithelial) as well as stromal (fibroblastic)
compartments. While prostate adenocarcinoma is ultimately an epithelial disease, it is
widely accepted that the stroma is involved in initiating, maintaining, and promoting a
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malignant phenotype through inter-cell signaling (103, 104). These processes may also
occur in TAHN tissues, as shown by Hanson and colleagues, who have reported promoter
methylation for GSTP1, RARβ2, and CD44 in stromal cells associated with tumors (104).
Additionally, this approach also demonstrates that the identified gene expression changes
could potentially be identified in biopsy samples. In the present study, we pooled samples
for the microarray analysis in order to minimize effects of sample heterogeneity. The
authenticity of our findings, however, was confirmed by qRT-PCR using RNA from
individual samples. Although heterogeneity from patient to patient was observed, data
validity was corroborated in an additional independent set of patient samples.
Although not comprehensive, Table 8 indicates part of a signature that may be
characteristic of prostatic field cancerized tissues. It is conceivable that many of the listed
transcripts could have an important role in prostatic TAHN tissues, either a causative one
as drivers of pre-malignancy or as a reaction to the presence of the tumor, or both.
Among the highest over-expressed transcripts in TAHN tissues were EGR-1, c-Fos, and
the growth/differentiation factor 15 (GDF-15), also called macrophage inhibitory
cytokine-1 (MIC1). EGR-1 has been strongly implicated in prostate cancer (82-89) and
regulates multiple target genes that in turn have a potential role in prostatic
carcinogenesis and progression, such as epidermal growth factor receptor (EGFR),
platelet derived growth factor (PDGF), and human telomerase reverse transcriptase
(hTERT), thereby regulating a spectrum of cellular responses, including growth and
growth arrest, survival and apoptosis, and differentiation and transformation (105, 106).
The involvement of c-Fos as part of the transcription factor activator protein 1 (AP-1)
that is activated downstream of many growth factors is supported by a large body of
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literature on oncogenesis and metastasis (107, 108). GDF-15 (MIC1) is a member of the
transforming growth factor  (TGF) family and is known to be up-regulated in prostate
cancer (109, 110). In addition, increased levels of GDF-15 have also been correlated with
metastasis and the development of sclerotic bone lesions, which are typical for prostate
cancer (110). It has also been shown to contribute to chemotherapeutic drug resistance
(111).
However, to fully characterize the extent and heterogeneity of prostatic field
cancerization, in this study we also chose transcripts that were not the highest overexpressed in TAHN tissues, such as TTP, FAS, and testican. TTP expression is not
specific to prostatic tissues. However, it is a ubiquitously expressed AU-rich element
(ARE) binding protein and a regulator of mRNA stability, including of pro-inflammatory
proteins, such as tumor necrosis alpha (TNFα) (112), which plays an important role in
prostate adenocarcinoma (113). It is possible that TNFα is produced by inflammatory
cells in TAHN tissues in agreement with the prominent role of inflammation as proposed
by De Marzo and colleagues (114). TNFα is a classical activator of the nuclear factor
kappa B (NFκB) pathway which is constitutively activated in prostate cancer with
prominent downstream targets that support an activated cellular state, including EGR-1
(105, 115). FAS has been termed a “metabolic oncogene” and may reflect a prostate
cell’s energetic switch to a more anaerobic yet more reductive physiologic state, which is
a hallmark of prostate cancer progression (91, 92). In addition, FAS has been shown to
positively affect NFκB nuclear translocation in cancer cells leading to an anti-apoptotic
effect (116). Finally, testican (SPOCK-1) belongs to the fibulin protein family of
extracellular matrix proteins which influence cell adhesion and migration, and have thus
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been associated with progression of several cancer types (117), including prostate cancer,
in which it has recently been shown to be up-regulated (90).
Collectively, our data supports the occurrence of field cancerization in prostatic
tissues and warrants further investigations into its underlying mechanisms and potential
clinical use of representative transcripts towards an improved prostate cancer detection
and patient outcome.
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Chapter 5
TC in matched biopsy and prostatectomy tissues

Specific Aim: Evaluate and compare the relationship between disease progression and
telomere content (TC) in cancerous and histologically normal prostate tissues obtained
from biopsy and prostatectomy.

Introduction: Telomeres are the protein-nucleic acid structures that stabilize and
protect the ends of the chromosomes. Normally 1-2,000 repeats of the hexanucleotide
sequence TTAGGG are found capping the DNA strands. Telomeres are shortened by 4050 nucleotides per round of replication due to steric inhibition by the DNA polymerase
binding to the leading strand during replication. When telomeres reach a critical length
senescence or apoptosis results in order to protect the integrity of the DNA of that cell.
However, multiple mechanisms in the cancerous cell, for example p53 and Rb mutations,
can bypass these checkpoints allowing further cell division. If neither senescence nor
apoptosis occurs and the telomeres continue to shorten, chromosome fusion, breakage,
and recombination ensues. Unchecked, these events lead to cell death, but in cancer cells,
telomeres are stabilized by the activation of telomerase, the enzyme that lengthens
telomeres.
Because telomerase is frequently activated in cancer cells, it follows that telomere
length of these cells will be different from normal, healthy cells, and this has indeed been
observed to be the case. Our laboratory has developed an assay to measure telomere
content (TC), a surrogate for telomere length, to evaluate telomeres of cancer and normal
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cells (39, 47). Additionally, our laboratory has used the TC assay to investigate field
effect in the tumor adjacent histologically normal tissues of breast and prostate cancer.
These studies have established that the telomeres of tumor cells are abnormal compared
to disease-free cells, that shorter telomeres are associated with a poorer outcome, and that
a field of genetically altered cells surrounds a tumor (17, 34, 37-39).
Based on our preliminary studies, we have proposed that TC predicts disease-free
survival in men with prostate cancer (Figure 4). To confirm and refine this finding, we
conducted a retrospective study comparing TC in cancerous and histologically normal
tissues from patient matched biopsy and prostatectomy specimens in which the patients
differ in recurrence outcome. The objective of this study was to determine whether TC
measured in tissue obtained by biopsy has diagnostic or prognostic value. Additionally,
this study investigated the relationship between TC in patient tissues obtained at biopsy
and subsequent prostatectomy.

Materials and Methods

Study cohort: The cases for this study were provided by Cooperative Prostate
Cancer Tissue Resource (CPCTR) in Pittsburgh, Pennsylvania. Slides provided included
a TAHN and tumor prostatectomy sample, and a cancerous tissue from biopsy; a portion
of the cases also included a histologically normal biopsy. For the purpose of this study,
sample sets were initially required to include all four tissue samples, although not all
samples yielded usable DNA. A total of 56 cases were chosen for analysis, of which 8
were African American and 48 were Caucasian. Gleason sum scores ranged from 5 to 8,
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with the majority being either Gleason Score 6 (22 cases) or 7 (30 cases). The median age
at time of prostatectomy was 63.5 years, with a range 47 to 79 years (Table 9). Of the 56
cases, 25 cases had recurrence as defined by PSA recurrence, and 31 cases did not recur
(Table 10).
Six prostate samples from cancer-free controls (sudden death cases) were
obtained from the National Cancer Institute Cooperative Human Tissue Network (CHTN;
Nashville, TN), stored at -70˚C, and subjected to DNA extraction and histological review.
The latter confirmed these samples to be free of both cancer and BPH. The median age of
this set was 44.5 years, with a range of 26-79 years.

DNA Isolation: DNA was isolated from formalin fixed, paraffin embedded tissue
mounted on glass slides. Sections were 10 m thick, unstained, and were derived from
either needle core biopsy or prostatectomy. If the specimen was from a biopsy, four slides
were used, if the sample was from a prostatectomy, two slides were used.
Slides were deparaffinized and rehydrated using xylene and decreasing concentrations of
ethanol. The tissue was scraped off the slide for DNA isolation using a commercial
isolation kit (Qiagen DNEasy Kit, Valencia, CA)

Quantification of DNA: DNA isolation was followed by quantitation with the
fluorescent dye, PicoGreen (Quant-iT Picogreen ® dsDNA Kit, Molecular Probes,
Eugene, OR) to determine the amount of double stranded DNA isolated according to the
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Table 9. Characteristics of the Telomere Content study cohort.
Patient demographics (cases)
Caucasian
African American
Age at Prostatectomy (years)
Range
Median
Mean
Gleason Score
5
6
7
8
Stage
T2a/b
T3
% gland occupied
<5%
5-25%
>25%

48
8
47-79
63.5
62.9
2
22
30
2
46
10
21
29
4

Table 10. Recurrence/follow up information of the Telomere Content study.

Recurrence
No Recurrence

Number of
patients
25
31

Median
(in
months)
27
62
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Mean
35.8
58.8

Min
14
17

Max
109
134

manufacturer’s protocol. Lambda phage DNA provided with the kit was used for the
control DNA to generate a standard curve. The control DNA standards and samples were
evaluated by excitation at 480nm and measuring the output at 520nm on a Luminescence
Spectrometer LS50 (Perkin Elmer, Boston, MA). Sample DNA concentrations were
calculated from the equation of the best-fit line generated from the standard control DNA.

Telomere Content assay: Our laboratory has previously developed an assay to
determine telomere content, an established surrogate for telomere length (37, 39, 47).
Patient samples were prepared at DNA concentrations ranging from 5-20 ng in TE buffer
in quadruplicate. A standard curve ranging from 0-40 ng was prepared using placental
DNA. Denaturing solution (0.05M NaOH, 1.5M NaCl) was added to the samples before
placing in a water bath at 56° C for 40 minutes. The samples were then removed from the
water bath and neutralizing solution (0.5M Tris, 1.5M NaCl) was added to the samples.
Samples were then loaded onto the prepared Tropilon-Plus Positively Charged Nylon
Membrane (Tropix, Bedford, MA) in the slot blot apparatus (Minifold® Slot-Blot
System, Schleicher & Schuell, Keene, NH). Membrane preparation included two washes
under vacuum with neutralizing solution. Following application of the samples under
vacuum, the blot was washed again with neutralizing solution and placed in 5X SSC for
10 minutes. The membrane was then air-dried and UV cross-linked with 1200 mJ (UVP,
Upland, CA). Next, the blot was wet with 0.25M sodium phosphate buffer, and then prehybridized in a glass hybridization bottle (Bellco Glass, Vineland, NJ) in prehybridization buffer (7% SDS, 0.25M sodium phosphate buffer, 0.001M EDTA, and 1X
Denhart’s Solution) for 1 hour at 60° C. Following pre-hybridization, hybridization

59

buffer (7% SDS, 0.25M sodium phosphate buffer, and 0.001M EDTA) with 500 pmols of
telomere probe was applied to the blot. The telomere probe is a telomere-specific FAM 3’
end labeled probe: 5’-(TTAGGG ) 4 -6-FAM-3’ (IDT, Coralville, IA). The blot was
incubated overnight at 60° C in this solution. Following hybridization, the blot was
washed 2 times in 2X SSC/1% SDS for 5 minutes, 2 times in 1X SSC/1% SDS for 15
minutes, and 2 times in 1X SSC for 5 minutes, respectively. Washes were carried out at
room temperature with the exception of the 1X SSC/1% SDS wash, which was done at
60° C. All washes were carried out in glass hybridization bottles.
In order to detect the fluorescein probe using the Southern Star
chemiluminescent kit (Tropix, Bedford, MA), the blot was blocked (1X PBS, 2% I Block
reagent (Tropix, Bedford, MA), and 0.1% Tween 20) for 40 minutes at room temperature.
This was followed by incubation in fresh blocking buffer with 0.5 uL of anti-fluoresceinAP Fab fragments antibody (Roche Diagnostics Corporation, Indianapolis, IN) for 2
hours at room temperature. The blot was washed for 5 minutes at room temperature with
fresh blocking buffer, then washed 3 times for 5 minutes with wash buffer (1X PBS and
0.1% Tween 20), also at room temperature. Next, the blot was incubated in 1X assay
buffer (Tropix, Bedford, MA) 2 times for 2 minutes each at room temperature to optimize
alkaline phosphatase activity. Finally, the blot was incubated with CDP-Star®
chemiluminescent substrate (Tropix, Bedford, MA) for 5 minutes and was then blotted
dry and sealed into plastic wrap for exposure to Hyperfilm ECL-Chemiluminescence film
(Amersham Biosciences, Buckinghamshire, England).
Following exposure, films were developed (Konica Medical Film Processormodel QX-70) and scanned (Hewlett-Packard ScanJet ADF). The digitized images were
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analyzed using Nucleotech Gel Expert Software 4.0 (Nucleotech, San Mateo, CA) in
order to determine the intensity of telomere hybridization signal. The TC values obtained
from each mass of the placental DNA standards were plotted and used to generate a
linear line equation. Sample telomere content is expressed as the ratio of the actual TC
measured for each sample mass to the TC predicted by the line equation, expressed as a
percentage.

Statistical Design: All statistical analysis was carried out using JMP IN version
3.2.1 from Statistical Analysis Software (SAS; Cary, NC). Differences in the means
between histologically normal tissue from biopsy, cancerous tissue from biopsy, TAHN,
and Tumor to cancer-free samples were analyzed using Student’s t-test; differences with
p<0.05 were considered statistically significant.

Results:
Telomere content in the six normal prostate tissues ranged from 94-121%. This
agrees well with the previously reported range of 75-143%, that defines TC in 95% of 70
normal tissue samples from multiple organ sources (17).
Telomere content of the histologically normal tissue from biopsies (n=15) ranged
from 25-217%, with a mean of 86% and median of 66%. Cancerous tissue from biopsy
telomere content (n=40) ranged from 7-220%, with a mean of 74% and a median of 66%.
The range for TAHN (n=33) was 17-355%, with a mean of 77% and a median of 58%.
Finally, Tumor (n=39) ranged from 11-360% with a mean of 66% and a median of 59%
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(Figure 13).The median of all sample groupings fell below the experimentally determined
normal telomere content range.
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0.0051
0.0011
0.0003

Figure 13. Telomere Content of samples by tissue source. The gray box indicates the
95% range of normal tissues as determined experimentally. Boxes contain the p-values
between the sample groups (Student’s t-test).
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Figure 14. Correlation of samples by tissue source. Paired samples by prostatectomy
or biopsy, and compared by relative tissue type. Panel A shows the TC relationship
between TAHN and Tumor tissues. Panel shows the TC relationship between Negative
and Positive Biopsy tissues. Panel C shows the lack of TC correlation between Positive
Biopsy and Tumor tissues. Panel D shows the lack of TC correlation between Negative
Biopsy and TAHN tissues.
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TC in TAHN and Tumor tissues in patient matched samples was strongly
correlated (n=29, r2=0.707, p=<0.0001, Figure 13) as was TC in TAHN and cancerous
tissues from patient matched biopsy specimens (n=14, r2=0.720, p=0.0001). Surprisingly,
TC was neither correlated in TAHN tissues from patient matched biopsy and
prostatectomy (n=11, r2=0.012, p=0.7498), nor cancerous tissues from patient matched
biopsy and prostatectomy (n=24, r2=0.035, p=0.3823) (Figure 14).

Discussion:
The results of these studies are similar to those reported previously for cancerous
breast samples (17, 34, 38) and cancerous prostate tissues (37, 38). Our prior studies
demonstrated that TC in tissues obtained from radical mastectomy and prostatectomy was
significantly reduced compared to disease-free prostate and breast tissues. More
importantly, these studies also found that the histologically normal tissue adjacent to the
tumor had significantly reduced TC compared to disease-free tissues.
The current study confirmed those findings in prostatectomy tissue, and extended
them to biopsy tissue. As expected, the findings were similar in the biopsy tissues to
those in prostatectomy tissues. Specifically, cancerous tissue from biopsy TC was
significantly reduced compared to disease-free tissue, and histologically normal tissue
from biopsy tissue was also significantly reduced in matched patient samples. These
findings indicate that TC in biopsy tissues may be informative of the presence of prostate
cancer. These findings indicate that it may be possible to detect abnormalities in biopsy
tissue indicative of cancer, potentially avoiding repeated biopsies and leading to earlier
treatment in cases that would otherwise have been missed on the basis of histology.
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The matched biopsy and prostatectomy samples used in this study enabled, for the
first time, an evaluation of two separate time points in patient matched samples. The
results demonstrate that TC in tissues from biopsy and prostatectomy specimens is
informative, regardless of histology. However, TC was not correlated between paired
histologically normal or cancerous biopsy and prostatectomy specimens. There are two
possible explanations for this: a) Temporal alterations and/or b) spatial alterations. It is
possible that telomere length is highly dynamic and constantly changing. The time
between biopsy and prostatectomy was unknown for the samples in this study, so it is
possible that the findings reflect ongoing changes in the abnormal cells. It is also possible
that the differences are due to the physical location within the prostate of the sample
collected. Biopsy samples are taken in a grid pattern and only sample a small portion of
the prostate, however, the general sampling area changes very little from patient to
patient. Tissues collected from prostatectomy specimens can come from any location
within the prostate. Additionally, unpublished data from our laboratory has found a high
level of heterogeneity within the prostate itself regarding TC. Based on that previous
work revealing a range of TC variation throughout the cancerous prostate and the
findings of TC correlation in prostatectomy specimens found by this study, it is more
likely that the TC correlation observed is due to spatial variation. However, temporal
effects cannot be ruled out, due to the lack of data regarding time between biopsy and
prostatectomy. More research will be needed to further elucidate this point.
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Chapter 6
Allelic Imbalance in matched biopsy and prostatectomy tissues

Specific Aim: Evaluate and compare the relationship between disease progression and
allelic imbalance (AI) in cancerous and histologically normal prostate tissues obtained
from biopsy and prostatectomy.

Introduction: Despite increased public awareness about prostate cancer and
Prostate-Specific Antigen (PSA) testing, prostate cancer rates continue to increase. This
is largely a direct result of increased detection. However, increased testing rates have also
demonstrated that PSA testing is not as reliable as once thought. While the current limit
to normal PSA levels is 4ng/mL, 20-30% of men with clinically confirmed prostate
cancer have normal PSA levels (4). To compound the problem, benign processes, such as
BPH and prostatitis, can elevate PSA levels, PSA does not differentiate between
cancerous and benign processes, and some men normally produce more PSA (4, 118).
Most frightening to cancer patients following treatment without prostatectomy, PSA
levels may actually rise temporarily depending on the type of treatment, causing great
distress (7). Yet, to date, no better biomarker has been found, either for detecting cancer
or for its prognosis (4). Based on our preliminary studies, we propose that AI, like TC,
predicts disease-free survival in men with prostate cancer. To confirm and refine this
finding, we proposed first to conduct a case-controlled study in which the patients differ
in disease stage at time of diagnosis and recurrence outcome. These experiments
determined if AI predicts disease recurrence independent of stage at diagnosis. Based on
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preliminary studies suggesting that AI can predicts disease-free survival in men with
differing pathological grades, we also proposed to determine if AI is suitable for
diagnosis and staging of prostate cancer, both in prostatectomy and, more importantly,
biopsy tissues. While a highly specific panel of microsatellite markers could be
developed, it is clear from our previous studies of breast and prostate tumors that
genomic instability is widespread and nonspecific. Because of this, a nonspecific test,
previously described (17), is being used.
Based on our preliminary studies, we proposed that AI, like TC, predicts diseasefree survival in men with prostate cancer (Figure 4). To confirm and refine this finding,
we conducted a retrospective study comparing AI sensitivity and specificity in both
biopsy and prostatectomy tissues to patient outcome, in which the patients differed in
disease stage at time of diagnosis and recurrence outcome. These experiments
investigated whether AI could be used to predict disease recurrence independent of stage
at diagnosis. Based on preliminary studies suggesting that AI can predict disease-free
survival in men with differing pathological grades, we also proposed to determine if AI is
more sensitive than PSA as a marker in prostate cancer diagnosis and staging.

Methods and Experimental Design

Specimen Acquisition: Slides were provided by the Cooperative Prostate Cancer
Tissue Resource in Pittsburg, Pennsylvania. Tissues provided included a malignant
prostatectomy sample, a benign prostatectomy sample, a cancerous biopsy sample and a
histologically normal biopsy sample where available. For the purpose of this study,
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sample sets were required to include all four tissue samples, although not all samples
yielded usable DNA. The study was comprised of a total of 56 cases, of which 49 were
Caucasian and 7 were African American. The range of ages at prostatectomy was 47-79
years, with a median of 63 years, a mean of 62 years. Gleason scores ranged from 5-8,
however only 2 were Gleason score 5 or 8. Twenty-two cases were Gleason score 6, and
the remaining 30 cases were Gleason score 7. Of the cases, 45 were staged T2a or b, and
11 were stage T3a or b (Table 11). Twenty-five cases recurred, with the median time to
recurrence being 27 months, and 31 cases remained disease-free at a median time of 63
months (Table 12).
Nine prostate samples from cancer-free controls (sudden death cases) were
obtained from the National Cancer Institute Cooperative Human Tissue Network (CHTN;
Nashville, TN), stored at -70˚C, and subjected to DNA extraction and histological review.
The latter confirmed these samples to be cancer-free and also free of BPH. The mean age
of this set was 36.6 years, the median was 43 years of age, and the range was 0-79 years.

DNA isolation: DNA was isolated as described in Chapter 5.

Allelic Imbalance Determination in Prostate Tumors: Allelic imbalance will
be evaluated using a PCR based assay similar to that described previously (45, 46),
developed in our laboratory. The AmpFlSTR® kit (Applied Biosystems, Foster City, CA)
contains reagents that amplify 16 different short tandem repeat (i.e. microsatellite) loci
within a single multiplex reaction. These 16 loci are located randomly throughout the
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Table 11. Patient cohort of the Allelic Imbalance study.
Patient demographics (cases)
Caucasian
African American
Age at Prostatectomy (in years)
Range
Median
Mean
Gleason Score
5
6
7
8
Stage
T2a/b
T3a/b

49
7
47-79
63
62.68
2
22
30
2
45
11

Table 12. Recurrence data among the Allelic Imbalance study cohort.

Recurrence
No
Recurrence

Number of
patients
25
31

Median time
to outcome
(months)
27
62

Mean
(months)
35.85
59.48
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Min (months)
14
17

Max (months)
109
134

genome and include Amelogenin, CSF1PO, D2S1338, D3S1358, D5S818, D7S820,
D8S1179, D13S317, D16S539, D18S51, D19S433, D21S11, FGA, TH01, TPOX, AND
vWA. The amplicons from this reaction are separated by capillary electrophoresis and
histograms of the fluorescently labeled products are generated. Approximately 1ng of
DNA will be amplified in a standard 25 l reaction mix according to the manufacturer’s
protocol. In each reaction there will be 10 l of the reaction mix, 5 l of the “Identifiler”
Primer Set and 2.5 U of AmpliTaq Gold DNA polymerase (Applied Biosystems,
FosterCity, CA). Cycling conditions include an initial denaturation at 95ºC for 11 min
followed by 30 cycles of 1 min at 94ºC, 1 min at 59ºC, and 1 min at 72ºC, with a final
extension of 60 min at 60ºC. PCR products will be resolved by capillary electrophoresis
and detected using an ABI Prism 377 DNA Sequencer (Perkin Elmer, Foster City, CA).
Two possible outcomes exist for this assay. When a locus is homozygous, i.e.
instances when a single peak is observed, a determination of loss of heterozigosity cannot
be made as there is no “normal” comparison population. Alternatively, when a locus is
heterozygous, i.e. the instances when two peaks are observed, the ratio of the peak
heights is used to determine if a sample is heterozygous or if it is imbalanced. Based on
our previously published studies, a site of allelic imbalance will be called when the ratio
is greater than 1.60 (17).

Statistical Design: JMP IN version 3.2.1 from Statistical Analysis Software
(SAS; Cary, NC) was used to analyze the study results. Differences in the means between
Negative Biopsy, Positive Biopsy, TAHN, and Tumor tissues and cancer-free samples
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were analyzed using the Student’s t-test; differences with p<0.05 were considered
statistically significant.

Results:
Allelic Imbalance was investigated in a total of 143 samples, 24 histologically
normal biopsy samples, 41 cancerous biopsy samples, 31 TAHN samples, 38 Tumor
samples, and 9 disease-free prostate samples. Seven of the normal samples had zero sites
of AI, and 2 samples had 1 site of AI for an average of 0.22 sites of AI per sample. These
results were consistent with our previous study of 118 normal tissues from various
organs. This demonstrated that approximately 75% and 25% of normal tissues have no
sites and one site of AI, respectively. Only one sample (0.8%) had 2 sites of AI. Overall,
there was an average of 0.27 sites of AI per sample (48).
In contrast to the normal tissues, the histologically normal biopsy samples had an
average of 1.92 sites of AI (p=0.0049), while the cancerous biopsy samples had an
average of 1.61 sites of AI (p=0.0001). Among the prostatectomy samples, TAHN tissues
had an average of 2.23 sites of AI (p=0.0006) and the Tumor tissues had 2.71 sites of AI
(p=<0.0001) on average (Figure 14).
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8

Number of sites of AI

7
6
5
4
3
2
1
0

Disease
free

Negative
Biopsy

Positive
Biopsy

TAHN

Tumor

0.0049
0.0001
0.0006
<0.0001

Figure 14. Allelic Imbalance. Allelic Imbalance of study cohort compared to normal
prostate tissues. Boxes indicate significance as determined by the Student’s t-test.

With multiple patient matched specimens, the opportunity arose to investigate
clonality between the field and the tumor cells populations. Additionally, because the
patient cases included both biopsy and prostatectomy specimens, clonality could also be
looked at over time, i.e. between biopsy and prostatectomy. We hypothesized that if a
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clonal relationship existed between the specimens, there would be matched sites of AI
between them, i.e. the same locus would be imbalanced in both the TAHN and Tumor
specimens. Analysis of the actual sites of AI was performed on three sub-populations:
paired biopsy samples, paired prostatectomy samples, and matched samples with data for
both biopsy and prostatectomy samples, resulting in groups of 4 pairs, 10 pairs, and 18
sets, respectively. Sites of AI in the patient matched cancerous biopsy specimens were
compared to the histologically normal biopsy specimens and sites of AI found in patient
matched tumor tissue were compared to TAHN (Table 14). While the four sets of
matched histologically normal and cancerous biopsies did not contain and matched sites
of AI, the 10 patient matched prostatectomy samples had 7 common sites of AI out of 17
possible instances (41.2%). In the 18 cases with all 4 tissues types providing data (Table
15), there were 12 instances of matched AI sites in the biopsy tissues out of 33 instances
of AI in the Negative Biopsy samples (36.4%); 11 matched sites existed with 46 possible
matches (23.9%) between tumor compared with TAHN. Nine sites of AI were found in 3
of the 4 tissue types (i.e. cancerous biopsy, TAHN, and tumor specimens), and 3 of these
cases had 2 instances of the conserved sites. Most interesting was the finding of 2 cases
with a conserved site of AI in all 4 samples.

Discussion:
Genomic instability is a common occurrence in cancer (13, 15, 119). Instability
can be reflected in loss of heterozigosity, and so other studies have endeavored to
determine if loss of heterozigosity at specific loci can be used to detect prostate cancer
(120, 121). However, this approach assumes that the genomic changes are
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Table 14. Clonality of allelic imbalance in paired specimens. Matched samples, either
Negative and Positive Biopsy or TAHN and Tumor. The lightest gray boxes indicate a
heterozygous or non-informative allele, the darker gray boxes indicate a site of
imbalance. The darkest boxes indicate a matched site of imbalance in the two tissue
types. The numbers at the left of the table indicate the case number. The following
column notates the sample type. The numbers across the top correlate to the allele tested.
Amelogenin was not included in the table as the entire cohort is male. 1-D8S1179; 2D21S11; 3-D7S820; 4-CSF1PO; 5-D3S1358; 6-THO1; 7-D13S317; 8-D16S539; 9D2S1338; 10-D19S433; 11-vWA; 12-TPOX; 13-D18S51; 14-D5S818; 15-FGA.
1
1
2
3
4
5
6
7
8
9
10
11
12
13
14

2

3

4

5

6

7

Neg Bx
Pos Bx
Neg Bx
Pos Bx
Neg Bx
Pos Bx
Neg Bx
Pos Bx
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
TAHN
Tumor
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8

9

10

11

12

13

14

15

Table 15. Clonaity of allelic imbalance in matched biopsy and prostatectomy
specimens. Cases including all four sample types: Negative Biopsy, Positive Biopsy,
TAHN, and Tumor tissue. The lightest gray boxes indicate sites of heterozigosity or
homozygous/non-informative alleles. Darker gray boxes indicate sites of allelic
imbalance. The darkest boxes indicate paired sites of allelic imbalance between either
Negative Biopsy and Positive Biopsy tissues or TAHN and Tumor tissues. In cases with
three common sites of imbalance between the sample types, the number indicates the
likelihood of imbalance between the three sample types. The numbers at the left of the
table indicate the case number. The following column notates the sample type. The
numbers across the top correlate to the allele tested. Amelogenin was not included in the
table as the entire cohort is male. 1-D8S1179; 2-D21S11; 3-D7S820; 4-CSF1PO; 5D3S1358; 6-THO1; 7-D13S317; 8-D16S539; 9-D2S1338; 10-D19S433; 11-vWA; 12TPOX; 13-D18S51; 14-D5S818; 15-FGA.
1
15

16

17

18

19

20

21

Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN

2

3

4

5

6

7

8

9

10

11

12

13

14

0.12
0.08

0.01

0.08

75

0.22

15

22

23

24

25

26

27

28

29

30

31

32

Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor
Neg Bx
Pos Bx
TAHN
Tumor

0.10

0.09

0.02

0.15

0.05

0.06
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consistent from case to case of prostate cancer. Viewed from the perspective that the
entire genome becomes unstable during carcinogenesis, the assay employed by our
laboratory reflects genome-wide genomic instability as opposed to locus-specific
instability. Additionally, our assay avoids the requirement of a ‘normal’ control sample,
reducing the amount of tissue or other biologic samples required from the patient, and
permitting evaluation of archival tissues where patient-matched normal tissue may not be
available. Because the assay is PCR based, only a small amount if tissue is required,
such as a biopsy needle core. Previous studies from our laboratory in both breast and
prostate cancers have demonstrated the presence of a field of genetically altered cells
surrounding the tumor as demonstrated by both altered TC and allelic imbalance (17, 48).
Taken together, these results demonstrate that AI in histologically normal tissue from a
cancerous prostate is indeed informative regarding genomic instability and the likelihood
of cancerous alterations being present, and does demonstrate the presence of a field of
altered cells is present. The current study confirmed this finding.
This is the first study to compare nonspecific sites of allelic imbalance in patient
matched biopsy and prostatectomy specimens using the assay developed within our
laboratory. AI was detected in both cancerous and histologically normal tissues from both
biopsy and prostatectomy specimens. Moreover, the numbers of sites of AI exceeded
those found in normal tissues and overlapped those found in cancers. These findings
indicate two things: a) a field of genetically altered cells are present at the time of biopsy
in cores determined to be histologically normal, and b) the number of sites of AI in both
cancerous and histologically normal tissues from needle core biopsies is informative of a
cancer diagnosis. However, it is important to point out that all of the patients in this
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cohort went on to prostatectomy due to the presence of prostate cancer. We have not yet
performed a comparable analysis of biopsies that did not result in a cancer diagnosis or
that contained only BPH or PIN. Thus, the conclusions of this investigation must be
viewed provisionally.
The interesting finding of this study arises from the finding of matched sites of AI
in patient matched tissues, such as TAHN and tumor specimens and biopsy and
prostatectomy specimens. These findings imply that the tumor cells may arise from a
clone found in the field of histologically normal, though genetically altered cells. Further,
these findings support the theory of clonal selection in cancer progression, evidenced by
the maintenance of a cell population containing specific genomic alterations. We interpret
instances in which site of AI were present in TAHN tissue but not in the matched Tumor
tissue to reflect genetically altered clones that did not give rise to the tumor, i.e. clones
that were not selected and constituted either a minority of the cell population or that were
lost completely. Most intriguing was the finding of conserved sites of AI in all for
specimens of a single case. The likelihood of conservation of a single site within all 4
specimens was determined to be 0.01% and 0.02% for the 2 cases, providing further
evidence that AI maintenance is not attributable to chance alone. The intriguing finding
of conserved sites of imbalance between samples supports the theory of clonality of
cancer cells and their precancerous progenitors. The results suggest that the abnormal
field of cells arise early, and eventually gives rise to the tumor, accumulating mutations
over time.
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